KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Novavax (NVAX) over the last 10 years, with Q3 2025 value amounting to $118.5 million.

  • Novavax's Other Operating Expenses rose 9553.94% to $118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.6 million, marking a year-over-year decrease of 4248.71%. This contributed to the annual value of $51.9 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Novavax's Other Operating Expenses is $118.5 million, which was up 9553.94% from $15.3 million recorded in Q2 2025.
  • Novavax's 5-year Other Operating Expenses high stood at $434.6 million for Q3 2022, and its period low was $14.1 million during Q1 2025.
  • Over the past 4 years, Novavax's median Other Operating Expenses value was $59.2 million (recorded in 2024), while the average stood at $106.5 million.
  • The largest annual percentage gain for Novavax's Other Operating Expenses in the last 5 years was 12419.1% (2023), contrasted with its biggest fall of 7942.39% (2023).
  • Over the past 4 years, Novavax's Other Operating Expenses (Quarter) stood at $181.8 million in 2022, then fell by 14.74% to $155.0 million in 2023, then crashed by 76.34% to $36.7 million in 2024, then skyrocketed by 223.25% to $118.5 million in 2025.
  • Its last three reported values are $118.5 million in Q3 2025, $15.3 million for Q2 2025, and $14.1 million during Q1 2025.